Entrada Therapeutics, Inc. (TRDA)

As of 14 August 2026, short interest in TRDA is 2,367,019 shares, up 136,322 shares over the last month. Over the last 48 readings it ranged from 760,344 shares (31 December 2025) to 2,367,019 shares (14 August 2026). The latest reading sits at the top of that range. At the reported average volume of 385K shares a day that is 6.2 days to cover, elevated.

<iframe src="https://xoomar.com/embed/stocks/trda" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>

As of 11 September 2026, the short share of TRDA volume is 34.5%, down 38.2 points over the last five sessions. Over the last 52 readings it ranged from 19.4% (19 August 2026) to 76.7% (4 September 2026). The latest reading is 15.8 points below the 30-session average of 50.2%, on 104K shares reported.

As of 4 August 2026, the fails-to-deliver balance in TRDA is 2,003 shares, up 2,002 shares over the last settlement date. Over the last 17 readings it ranged from 1 share (29 July 2026) to 54,878 shares (3 March 2026). The latest reading sits at the bottom of that range.

Insiders at TRDA reported 9 open-market sells worth $3.1M in the last 90 days and no open-market buys. Sells alone are a weak signal; insiders sell for tax, diversification and estate reasons all the time. Latest filing: PARMAR KUSH on 2026-08-10.

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are the rarer, stronger signal.

2 Form 144 notices on file for TRDA worth $3.3M at the prices reported; 2 in the last 90 days worth $3.3M. Latest: 5AM Ventures V, L.P. filed on 2026-08-10 to sell 165,578 shares ($1.1M) from 2026-07-30.

13 holders above 5% have filed on TRDA, 13 on Schedule 13D (active intent). The largest reported stake is ANSBERT GADICKE at 9.9% of the class (3,885,115 shares), filed 2026-09-10 for an event on 2026-09-08.

7 of the 30 tracked managers held TRDA at their latest 13F, $15.9M in total at quarter-end prices. Millennium Management is the largest at $5.6M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 4 added shares and 2 cut.

Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.

In Q2 2026 (quarter ended 2026-06-30) Entrada Therapeutics, Inc. reported revenue of $898K, down 53.9% from the same quarter a year earlier, and net loss of $42.8M (-1.01 diluted EPS). In FY 2025 it generated -$128.5M of operating cash flow.

Quarterly, last 8 quarters

Fiscal years, with buybacks and dividends

Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are cash paid to repurchase common stock in the year (XBRL PaymentsForRepurchaseOfCommonStock), not authorizations. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-31 from the cover page.